成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)
Mini Samples ELISA Kit for Fibroblast Growth Factor 23 (FGF23)
ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
- 編號(hào)UMEA746Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍15.6-1,000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于6.2pg/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1588 ¥ 2268 ¥ 10206 ¥ 19278 ¥ 158760
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 84-104 | 95 |
| EDTA plasma(n=5) | 88-95 | 91 |
| heparin plasma(n=5) | 82-98 | 89 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-97% | 78-93% | 84-102% | 83-97% |
| EDTA plasma(n=5) | 89-96% | 95-104% | 94-101% | 85-98% |
| heparin plasma(n=5) | 84-101% | 80-92% | 89-96% | 78-101% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）25µL，37°C溫育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A25µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B25µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物25µL，37°C孵育10-20分鐘；
8. 加終止液20µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA746Hu01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA746Hu02 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA746Hu03 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA746Hu03 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA746Hu04 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA746Hu01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)活性蛋白 | Cell?culture;?Activity?Assays. |
| UPAA746Hu02 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體 | IHC |
| UPAA746Hu03 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體 | IHC |
| UPAA746Hu04 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體 | WB |
| UPAA746Hu01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體 | WB; IHC |
| ULAA746Hu71 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| URAA746Hu21 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| UMAA746Hu23 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體 | ICC/IF |
| UMAA746Hu22 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA746Hu21 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體 | WB |
| ULAA746Hu72 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMEA746Hu | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USEA746Hu | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA746Hu | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Journal of international medicine | Prognostic impact of renal function in precapillary pulmonary hypertension [Pubmed: 24011362] |
| BMC Nephrology | FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients [Pubmed: 24180481] |
| Journal of Clinical Densitometry | Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism [Pubmed: 23623649] |
| J Intern Med. | Prognostic impact of renal function in precapillary pulmonary hypertension. [Pubmed:24011362] |
| Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth [Pubmed:25639729] |
| Nefrologia | Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina [PubMed: 26394828] |
| Medicine (Baltimore) | An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer [PubMed: 26266370] |
| Ann Biol Clin (Paris) | Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique? [PubMed: 26069069] |
| Scandinavian Journal of Gastroenterology | High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23 [Pubmed:27326766] |
| PLOS?ONE | Prostaglandin-E2?Mediated?Increase?in?Calcium?and?Phosphate?Excretion?in a?Mouse?Model?ofDistal?Nephron?Salt?Wasting. [pubmed:27442254] |
| Journal of Laboratory Diagnostics | Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation [publication:312592751] |
| Journal of Integrative Nephrology & Andrology | Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients [issn:2394-2916] |
| Journal of Renal Nutrition | ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder. [pubmed:29056164] |
| Experimental Biology and Medicine(Maywood) | Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats [Pubmed:29763365] |
| Psychiatry Research | Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity [Pubmed:29677623] |
| BMC?Pediatrics | Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children [Pubmed:29907141] |
| Medical Science Monitor | Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study [Pubmed:29608553] |
| International Journal of Chronic Obstructive Pulmonary Disease | Disconnection of pulmonary and systemic arterial stiffness in COPD [Pubmed:29881265] |
| Saudi?journal of?kidney?diseases and transplantation | Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients [Pubmed:29970732] |
| Nephrology Dialysis?Transplantation | High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease [Pubmed: 30189026] |
| BioFactors? | Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma [Pubmed: 30334297] |
| Biological?Trace?Element?Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients [Pubmed: 30847765] |
| Clin Implant Dent Relat Res. | Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases [Pubmed: 31407857] |
| JACC-Cardiovascular Imaging | PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS [Pubmed: 28797410] |
| Saudi J Kidney Dis Transpl | Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease [Pubmed: 31696838] |
| Biomedicine & Pharmacotherapy | MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7 [Pubmed: 31918268] |
| Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis? [] | |
| THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS [] | |
| THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ?- [] | |
| Calcif Tissue Int | The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations [Pubmed:35665817] |
| European Journal of Medical Genetics | Genetic and clinical profile of patients with hypophosphatemic rickets [Pubmed:35738466] |
| African Health Sciences | Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease [] |
